Transgene 'delay' with lung cancer vaccine not necessarily bad
This article was originally published in Scrip
Transgene is facing a delay with its lung cancer vaccine TG4010, the subject of an option agreement with Novartis, but the development does not necessarily spell bad news. Transgene has reported that the number of disease-progression events required per protocol to perform the progression-free survival (PFS) analysis for the Phase IIb part of the TIME study was reached later than had been expected. This has resulted in a delay in the time to topline data, which had been due this quarter.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.